In vitro Quantitative Imaging Assay for Phagocytosis of Dead Neuroblastoma Cells by iPSC-Macrophages
February 14th, 2021
7.1K views
Neurodegenerative diseases are associated with dysregulated microglia functions. This article outlines an in vitro assay of phagocytosis of neuroblastoma cells by iPSC-macrophages. Quantitative microscopy readouts are described for both live-cell time-lapse imaging and fixed-cell high-content imaging.
Overview
This article presents a rapid, scalable in vitro microscopy protocol to quantify microglial efferocytosis using an induced pluripotent stem cell (iPSC) model of microglia and pH-sensitive dye-labeled human neuroblastoma (SH-SY5Y) cells as phagocytic cargo. The assay is optimized for high-content imaging, enabling detailed analysis of microglial phagocytic function and its modulation by genetic or pharmacological factors relevant to neurodegenerative diseases.
Key Study Components
Area of Science
- Neuroimmunology
- Cell Biology
- Neurodegenerative Disease Research
Background
- Microglia are central to neuroimmune responses in diseases such as Parkinson's and Alzheimer's.
- Efferocytosis is a specialized form of phagocytosis by which microglia clear dead or dying neurons.
- Disruption of microglial phagocytosis is implicated in neurodegenerative disease pathology.
- Existing assays for microglial efferocytosis are often labor-intensive or not easily scalable.
Purpose of Study
- To develop a simple, rapid, and scalable in vitro assay for quantifying microglial efferocytosis.
- To enable high-content imaging and screening of genetic or pharmacological modulators of microglial phagocytosis.
- To validate the assay using known inhibitors and demonstrate its adaptability for other phagocytic cargoes.
Methods Used
- Preparation of dead SH-SY5Y neuroblastoma cells labeled with a pH-sensitive red fluorescent dye.
- Co-culture of labeled SH-SY5Y cells with iPSC-derived macrophages in 96-well plates.
- Live-cell time-lapse and fixed-cell high-content microscopy to quantify phagocytosis.
- Validation using phagocytosis inhibitors (Cytochalasin D, Jasplakinolide, Bafilomycin A1, Annexin 5).
Main Results
- The number of phagocytosed particles per cell increased linearly with time at optimal cargo concentrations.
- Phagocytosis was significantly inhibited by Cytochalasin D (~50% in live-cell, 91% in fixed-cell), Jasplakinolide (90%), Bafilomycin A1 (31%), and Annexin 5 (30%).
- Fixed SH-SY5Y cells exposed phosphatidylserine, confirming their suitability as efferocytic cargo.
- The assay is compatible with both live and fixed-cell imaging and can be scaled for high-throughput screening.
Conclusions
- This protocol enables robust, quantitative assessment of microglial efferocytosis in vitro.
- The assay is adaptable for different phagocytic cargoes and cell types relevant to neurodegenerative disease research.
- It provides a platform for screening genetic variants and small molecule modulators of microglial function.
Frequently Asked Questions
What is the main advantage of this microglial efferocytosis assay?
The assay is rapid, scalable, and compatible with high-content imaging, making it suitable for screening genetic or pharmacological modulators of microglial phagocytosis.
How are the phagocytic cargo cells prepared?
SH-SY5Y neuroblastoma cells are fixed, labeled with a pH-sensitive red fluorescent dye, and confirmed to expose phosphatidylserine, an "eat-me" signal for phagocytes.
Can this assay be used for live-cell imaging?
Yes, the protocol supports both live-cell time-lapse imaging and fixed-cell high-content microscopy.
How is phagocytosis quantified in this assay?
Phagocytosis is quantified by counting the number of fluorescent cargo particles internalized per microglial cell using automated high-content microscopy.
What inhibitors were used to validate the assay?
Cytochalasin D, Jasplakinolide, Bafilomycin A1, and recombinant Annexin 5 were used, each significantly reducing phagocytosis as expected.
Is the assay adaptable to other phagocytic cargoes?
Yes, the protocol can be adapted for other cargoes such as synaptosomes and myelin, as well as other phagocytic cell types.
What are the potential applications of this assay?
The assay can be used to study the effects of genetic variants, environmental factors, or small molecules on microglial phagocytosis in the context of neurodegenerative diseases.
Executive Industry Relevance
Quantitative imaging of iPSC-macrophage phagocytosis of dead neuroblastoma cells provides a scalable, high-content assay for interrogating microglial efferocytosis relevant to neurodegenerative disease. This platform enables robust, reproducible evaluation of genetic and pharmacological modulators, supporting predictive confidence in early discovery and target validation. Its adaptability and throughput position it as a critical tool for risk-adjusted portfolio advancement in neuroimmunology pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables quantitative assessment of microglial efferocytosis across genetic backgrounds and treatments.
- Supports mechanistic de-risking by validating functional consequences of candidate targets or variants.
- Facilitates hypothesis-driven interrogation of neuroimmune pathways implicated in disease.
Screening & Assay Development
- Delivers standardized, scalable 96-well plate format for high-content imaging and screening.
- Provides reproducible, quantitative outputs suitable for small molecule or genetic variant evaluation.
- Enables assay adaptation for diverse phagocytic cargoes and cell types relevant to neurodegeneration.
Translational & Preclinical Research
- Aligns in vitro phagocytosis readouts with disease-relevant neuroimmune mechanisms.
- Supports continuity from discovery through preclinical validation of microglial function modulators.
- Enables risk-adjusted advancement decisions based on quantitative, mechanistic data.
Pipeline & Workflow Integration
This assay bridges early discovery, target validation, and preclinical research by providing a quantitative, scalable platform for functional microglial assessment.
- Discovery Biology: Quantifies efferocytosis to clarify neuroimmune pathway involvement and target function.
- Screening: Standardizes high-content imaging for reproducible, scalable compound or variant evaluation.
- Analytics: Generates quantitative phagocytosis metrics for robust statistical comparison across conditions.
- Translational Research: Aligns in vitro functional outputs with disease-relevant neuroimmune endpoints.
- Enterprise Reuse: Adaptable protocol supports diverse phagocytic cargoes and cell types for broad R&D utility.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in neuroimmune target validation.
- Operational Value: Enables assay standardization, reproducibility, and high-throughput scalability.
- Strategic Value: Informs go/no-go decisions and enhances capital efficiency by de-risking early-stage assets.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of neuroimmune therapeutic candidates.
Implementation Considerations
- Requires expertise in iPSC culture, neuroblastoma cell handling, and high-content imaging.
- Demands access to automated microscopy and quantitative image analysis infrastructure.
- Standardization of cargo preparation and staining protocols is critical for reproducibility.
- Protocol is adaptable to other phagocytic cargoes and cell types with appropriate validation.
- Throughput and segmentation accuracy may be limited by cell density and imaging field crowding.
Biopharma FAQs
Why does null hypothesis testing matter for phagocytosis quantification?
Null hypothesis testing enables objective evaluation of whether observed differences in phagocytosis rates between treatments or genotypes are statistically significant, supporting robust target validation and mechanistic de-risking in discovery workflows.
How does independent variable isolation fit the iPSC-macrophage assay pipeline?
Isolating variables such as genetic background or compound treatment in the 96-well assay format allows precise attribution of changes in phagocytic function, facilitating clear interpretation of experimental outcomes for early-stage decision making.
What do quantitative dependent variable measurements enable in high-content imaging?
Quantitative measurement of phagocytosed particles per cell provides reproducible, scalable data for comparing functional outcomes across experimental conditions, supporting screening and prioritization of modulators in neuroimmune research.
Why are replication requirements critical for cross-functional collaboration in this assay?
Replication ensures that observed effects on phagocytosis are robust and reproducible, enabling reliable data sharing and interpretation across discovery, screening, and translational teams within biopharma organizations.
What statistical analysis capabilities are required before implementing high-content phagocytosis assays?
Implementation requires statistical tools for comparing phagocytosis rates, assessing significance, and controlling for variability, ensuring that assay outputs support confident, data-driven advancement decisions in the R&D pipeline.
Chapters in this video
0:04
Introduction
0:41
Preparation of Dead SH-SY5Ys
2:03
Labeling of Dead SH-SY5Ys with pH-Sensitive Red Fluorescent Dye
3:18
Staining of iPSC-Macrophages
4:50
Fixed-Cell High-Content Imaging
7:28
Results: Imaging, Optimization and Validation of Phagocytosis Assay
9:16
Conclusion
